Biotech stock price movements, volume anomalies, financial trends, and public market evaluations.
Deep analysis of the FDA's June 29, 2026 announcement of seven companies selected for the PreCheck Pilot Program — what the selection criteria actually were, who the winners are, what their facility investments look like, and what this means for each company's strategic positioning, the broader CDMO landscape, and the US biopharma supply chain.
Across our internal biotech cohort, 71 publicly-verified upcoming catalyst events sit in the database — 17 with exact PDUFA/readout dates, 51 in sponsor-stated quarters, and 3 still TBD. Today's breakdown covers Q3 2026 (17), Q4 2026 (18), and H1 2027 (12), plus the cross-cutting conference placements, the 41 H1-2026 items we deliberately crossed off the calendar, and one notable caveat (an outlook-therapeutics 4th BLA resubmission) that explains why some 'exact date' PDUFAs are actually long-shot recoveries.
A daily synthesis of the 154 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-06-26 (post-market, Friday). Curis up 55.98% on 178x volume. Tvardi down 36.44% on 33x volume. Sector rotation into devices, psychedelics, and implants. 154 names moved |%|>= 5%. The full report is at the bottom.
A daily synthesis of the 105 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Today's signal: AI-designed and psychedelic-adjacent drug-discovery platforms are being rewarded on clinical validation (ABSI +34.75%, DFTX +18.23%), while orphan-disease single-asset micro-caps are being punished on dilution (CGTX -34.33%, NUWE -33.52%). Includes a 6-class taxonomy of mover signal and the underlying catalysts for the top 6 movers.